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Abstract
Large scale clinical trials demonstrate significant reductions in cardiovascular event rates
with statin therapy. The observed benefit of statin therapy, however, may be larger in these
trials than that expected on the basis of lipid lowering alone. Emerging evidence from both
clinical trials and basic science studies suggest that statins have anti-inflammatory
properties, which may additionally lead to clinical efficacy. Measurement of markers of
inflammation such as high sensitivity C-reactive protein in addition to lipid parameters may
help identify those patients who will benefit most from statin therapy.
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Introduction
Hyperlipidemia is a major risk factor for atherosclerosis,
and several large scale trials demonstrate that cholesterol
lowering therapy with 3-hydroxy-3-methyl coenzyme A
(HMGCoA) reductase inhibitors reduces coronary event
rates in both primary and secondary prevention [1–5].
Paradoxes revealed by these trials, however, raise the
possibility that statins may have effects that go beyond
simple lipid reduction.
Despite large reductions in cardiac event rates, the
absolute angiographic change in arterial narrowing
observed with statin therapy is small [6]. Second, several
trials suggest that the observed clinical benefit of statin
therapy is greater than that expected on the basis of low
density lipoprotein (LDL) reduction alone. For instance,
when the Framingham coronary heart disease model was
applied to the West of Scotland Coronary Prevention
Study (WOSCOPS) population, the model accurately pre-
dicted risk in the placebo group but underestimated the
risk reduction in the pravastatin group [2]. The benefits of
LDL reduction with statins also appear to occur earlier
than is observed with other cholesterol lowering therapies
such as cholestyramine and ileal bypass surgery, even
among patients with similar levels of cholesterol after
therapy [7,8]. Finally, statins reduce the risk of stroke, but
LDL is not an important risk factor for stroke [9].
One additional mechanism by which statins may reduce
vascular event rates relates to potential anti-inflammatory
effects of these agents. Inflammatory processes, in this
regard, play a pivotal role in the pathogenesis of athero-
sclerosis, and elevated plasma levels of markers of inflam-
mation such as high sensitivity C-reactive protein
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(hs-CRP), serum amyloid A, IL-6 and soluble intercellular
adhesion molecule-1 have been shown to predict cardio-
vascular events [10–16]. 
Laboratory evidence for anti-inflammatory
effects of statins
Unstable plaques are characterized by active inflammation
that overwhelms the plaque’s capacity for repair [17].
Macrophages and T cells are abundant in the regions of
plaque rupture, while smooth muscle cells are few. Stable
plaques, conversely, contain few inflammatory cells and
abundant smooth muscle cells.
Numerous studies suggest important effects of statins on
macrophage function. Macrophages are capable of
degrading the extracellular matrix and, by secreting matrix
metalloproteinase (MMP), may weaken the fibrous cap
and thus predispose an atheromatous plaque to rupture.
Fluvastatin and simvastatin have recently been shown to
inhibit MMP-9 (gelatinase B) activity and secretion by
macrophages [18]. This effect is reversed by the addition
of mevalonate, suggesting that it is mediated by HMGCoA
reductase inhibition.
MMP-1, or interstitial collagenase, is also thought to play a
role in atherosclerotic plaque rupture. Fluvastatin appears
to decrease MMP-1 expression in human vascular
endothelial cells in a time- and dose-dependent manner
[19]. This effect is also seen with lovastatin and again is
completely blocked by coincubation with mevalonate. The
concentration of fluvastatin required to reduce MMP-1
expression is similar to that seen in clinical practice.
Pravastatin has been shown to cause changes in the com-
position of atheromatous plaque independent of its choles-
terol lowering effect. Pravastatin-treated monkeys have
better vasodilator function and favorable changes in the
composition of atheromatous plaque compared with control
animals with similar changes in lipid profile caused by diet
alone [20]. The pravastatin-treated monkeys had fewer
macrophages in the intima and media, less calcification and
less neovascularization in the intima. Pravastatin may thus
serve to stabilize vulnerable plaques by promoting regres-
sion of fragile, rupture prone microvessels in the intima.
Oxidized LDL is a key player in the atherogenic pathway.
The uptake of oxidized LDL by macrophages generates
lipid rich foam cells. Oxidized LDL causes monocyte
tissue factor expression, and the proliferation and apopto-
sis of smooth muscle cells [21,22]. Oxidized LDL also
inhibits nitric oxide synthase activity and hence impairs
endothelium-dependent vasodilation [23].
Statins reduce the susceptibility of LDL to oxidation by a
variety of mechanisms. Statins reduce the cholesterol
content of lipoproteins through their hypocholesterolemic
effects, and thus lower the amount of substrate available
for oxidation [24]. Simvastatin has been shown to reduce
macrophage superoxide formation, thereby decreasing
cell oxygen production [25]. Fluvastatin and lovastatin
bind to phospholipid on the surface of LDL and thus
prevent diffusion into the lipoprotein core of free radicals
generated under oxidative stress [26]. Atorvastatin and flu-
vastatin have also been shown to have direct antioxidant
potential [27,28].
Statins can directly upregulate endothelial nitric oxide syn-
thase (eNOS) expression in vitro under cholesterol
clamped conditions [23]. Both simvastatin and lovastatin
upregulate eNOS expression almost fourfold, and com-
pletely prevent its downregulation by oxidized LDL. The
upregulation of eNOS was reversed by the addition of
mevalonate.
A significant increase in endothelium-dependent vasodila-
tion in patients with moderate hypercholesterolemia has
been observed after 4 weeks of treatment with simvastatin
[29]. The neuroprotective effect of statins is absent in
eNOS deficient mice, suggesting that enhanced eNOS
activity by statins is a main mechanism by which HMGCoA
reductase inhibitors protect against cerebral injury [30].
Hypercholesterolemic rats treated with fluvastatin have
attenuated leukocyte adherence responses to platelet
activation factor and leukotriene B4 [31]. Statins inhibit
the expression of CD-11b on the cell surface, thus reduc-
ing the adhesiveness of macrophages to the vascular
endothelium [32]. Atorvastatin reduces monocyte
chemoattractant protein-1 levels in the intima and media in
hypercholesterolemic rabbits [33]. This decrease in mono-
cyte chemoattractant protein-1 is related to a reduction in
nuclear factor kB activation, a transcription factor involved
in the induction of monocyte chemoattractant protein-1
and other proinflammatory cytokines such as IL-1b and
tumor necrosis factor-a (TNF-a). 
Statins also cause decreased macrophage expression of
soluble intercellular adhesion molecule-1 and lipopolysac-
charide-induced secretion of IL-6 and TNF-a by mono-
cytes and macrophages [34–36]. Recent data show that
simvastatin therapy for 8 weeks reduces monocyte expres-
sion of TNF-a and IL-1b by 49 and 35%, respectively
[37]; this is intriguing data because elevated plasma levels
of both soluble intercellular adhesion molecule-1 and IL-6
have been shown to predict risk for myocardial infarction
[12,13]. A recent analysis from the Cholesterol and Recur-
rent Events (CARE) trial showed that plasma concentra-
tions of TNF-a are also persistently elevated among
postmyocardial infarction patients at increased risk for
coronary events [38]. These findings provide supportive
evidence that anti-inflammatory effects of statins may
make an important contribution to their clinical efficacy.c
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In addition to reducing synthesis of cholesterol, HMGCoA
reductase inhibitors lower levels of isoprenoids, which are
derived from intermediates in the cholesterol biosynthetic
pathway. Isoprenoids prenylate a number of cellular pro-
teins that play key roles in cell growth and signal transduc-
tion pathways such as G proteins, which have been
shown to modulate mitogenic pathways [39].
Statins have been reported to induce apoptosis in cultured
vascular smooth muscle cells, and both atorvastatin and
fluvastatin increase apoptosis in injured carotid arteries in
rabbits [40]. Both simvastatin and fluvastatin inhibit smooth
muscle cell proliferation, while pravastatin is devoid of such
an effect [41]. The hydrophilic nature of pravastatin may
thus limit its diffusion through cell membranes.
Statins also have potentially favorable effects on the coag-
ulation profile. Tissue factor is the primary initiator of the
extrinsic pathway. Lipophilic statins (simvastatin and flu-
vastatin) have been shown to decrease tissue factor
expression and activity in cultured human monocyte
derived macrophages [42]. Statins also increase tissue
plasminogen activator levels and cause a concomitant fall
in plasminogen activating inhibitor-1 activity [43].
Other in vivo effects common to statins include a reduction
of platelet aggregation ex vivo and in vitro [44]. Simvastatin
and pravastatin have been shown to reduce thrombus for-
mation and inhibit thrombin generation [45,46].
Pravastatin therapy is associated with a reduction in the
number of episodes of rejection following cardiac trans-
plantation. The inhibition of natural killer T cell activity by
pravastatin may explain, in part, this beneficial effect [47].
Although transplant vasculopathy is an entity distinct from
atherosclerotic disease, similar inflammatory mediators
may contribute to plaque instability.
Evidence from clinical trials for anti-
inflammatory effects of statins
Clinical data regarding the anti-inflammatory role of statins
has until recently been limited. Intriguing data from the CARE
trial suggests that pravastatin may directly attenuate the
adverse effects of inflammation in a process independent of
LDL lowering. The CARE trial specifically randomized
patients with a prior history of myocardial infarction to receive
either 40 mg pravastatin daily or placebo [1]. Patients with
evidence of persistent inflammation (as evidenced by eleva-
tion of both hs-CRP and serum amyloid A) were at increased
risk for recurrent cardiovascular events [48]. The study group
with the highest risk of recurrent events was that of patients
with persistent evidence of inflammation who were assigned
to placebo (relative risk = 2.81, P= 0.007). In a stratified
analysis, however, the association between inflammation and
risk was significant among those randomized to placebo (rel-
ative risk = 2.11, P= 0.048) but was attenuated and not sig-
nificant among those randomized to pravastatin (relative
risk = 1.29, P= 0.5). The proportion of recurrent cardiac
events prevented by pravastatin was 54% among those
patients with persistent evidence of inflammation compared
with 25% among those without inflammation (Fig. 1). This
difference in benefit was observed despite identical baseline
LDL levels in these two groups. Compared with placebo,
moreover, pravastatin therapy resulted in a 22% reduction in
median hs-CRP levels over a 5 year period (Fig. 2), an effect
that was independent of statin-induced changes in LDL [49].
Taken together, these data suggest that, in addition to lower-
ing LDL cholesterol, pravastatin may have clinically important
anti-inflammatory properties.
Figure 1
Relative risks of recurrent coronary events among postmyocardial
infarction patients according to the presence or absence of ongoing
inflammation and according to placebo or pravastatin therapy.
(Adapted from Ridker et al [48].)
Figure 2
Median (solid lines) and mean (dotted lines) levels of hs-CRP at
baseline and at 5 years among participants in the CARE trial,
according to placebo or pravastatin assignment. (Adapted from Ridker
et al [49]).Atorvastatin and simvastatin have also been shown to
reduce CRP levels in a small study of 66 hyperlipidemic
patients with coronary artery disease [50]. Simvastatin has
been found to reduce CRP levels in type II diabetic
patients with hyperlipidemia [51]. The observed change in
CRP did not correlate with changes in total cholesterol or
high density lipoprotein.
The relative importance of hs-CRP reduction compared
with LDL reduction is currently uncertain, and several
ongoing studies are directly addressing this issue. What is
clear, however, is that markers of inflammation such as
hs-CRP appear to add to the predictive value of lipid
screening in terms of predicting cardiovascular risk (Fig. 3)
[11,52]. It is also clear, at least in secondary prevention,
that statins lower hs-CRP levels even in the absence of
hyperlipidemia. It has thus been hypothesized that screen-
ing for inflammatory markers may provide an improved
method to target statin therapy in primary prevention. 
It is not currently known if all statins have clinically relevant
anti-inflammatory effects or whether any one agent is more
powerful than another is in this regard. Furthermore, the
time course of the anti-inflammatory effects of statins is
not known. Clinical trials with head to head comparison of
statins (such as the PROVE-IT study) and studies
designed to examine the time-course of statin therapy on
hs-CRP levels (such as the PRINCE trial) will help to
resolve these remaining questions [53].
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